Dexcom (DXCM) Stock Price, Fundamentals & Analysis

What DXCM does

Dexcom (DXCM) is a US medical device company headquartered in San Diego, employing around 11,000 people. It designs and sells continuous glucose monitoring (CGM) systems used for diabetes and metabolic health management in the United States and internationally. Its product line includes the Dexcom G7 and G7 15 Day systems, Dexcom G6, Dexcom ONE+ (which replaces fingerstick testing), Stelo (a biosensor for adults with prediabetes or Type 2 diabetes who do not use insulin), plus the Dexcom Share remote monitoring system and the Dexcom Follow app. Products are marketed directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999.

It operates in the Healthcare sector, Medical Devices industry, alongside peers such as Medtronic (MDT), [Abbott-listed competitor coverage like Thermo Fisher Scientific (TMO), and Edwards Lifesciences (EW).

Key numbers explained

• Price: 87.73 USD, down -2.01% today. Over the last 52 weeks the stock moved between 54.11 and 92.59 USD, and gained 32.6% from a year ago.
• Market capitalisation — the total value of all shares — is 33.11B USD, which places Dexcom among the larger medical device companies.
• The trailing P/E ratio of 34.7 means the price equals about 34.7 years of current earnings; the forward P/E of 28.1 is lower because expected earnings are higher.
• Earnings per share over the trailing 12 months are 2.53 USD.
• The dividend yield is 0% — Dexcom pays no dividend and pays out 0% of earnings, reinvesting profits instead.
• Revenue over the trailing 12 months is 4.97B USD, growing 13.1% year over year.
• Profitability is strong: a 20.1% profit margin, 24.3% operating margin, and 38.5% return on equity.
• A beta of 1.42 suggests the stock has historically moved more sharply than the overall market; the price-to-book ratio of 12.63 and a debt-to-equity ratio of 53.3% round out the picture.

Recent news

Headlines have covered the wearable biosensors market, naming Dexcom alongside Abbott, Medtronic, Roche, Apple, Samsung, and Garmin in forecasts to 2036. Truist Securities adjusted its DexCom price target to $102 from $93 while maintaining a Buy rating, and a recent SEC filing showed an insider sold shares worth $679,769. Other articles discussed Nasdaq 100 stock picks and less-followed stocks, with Dexcom appearing among them.

What to watch

As a medical device maker, Dexcom's results depend on CGM adoption, reimbursement policies, competition in glucose monitoring, and new product uptake such as Stelo. General factors include healthcare spending trends, regulatory decisions, currency movements affecting international sales, and broader market conditions — its beta of 1.42 indicates sensitivity to market swings. The next earnings date is Oct 29, 2026.